The 30th National High School Manga Championship (Manga Koshien)
19.7.2021 08:30:00 EEST | Business Wire | Press release
Manga Koshien is a competition where high school students compete for the position of Number 1 by creating one-page manga since 1992.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210718005034/en/
poster (Graphic: Business Wire)
About 300 high school teams, comprising three to five students each, enter every year. Of these, 30 teams are selected to go on to the championship round in August. Competing teams battle it out with their ideas, techniques and teamwork, all within a limited amount of time.
Talented students participating in the main round may also be scouted by major manga publishers and perhaps even debut as professionals!
[ The 30th Manga Koshien ]
As this year’s tournament is celebrating the 30th anniversary of our event, we will advance a total of 40 teams, 10 more than usual, to the final.
There are various events by professional manga artists between the competitions, and it will be a spectacular delivery. Please take a look.
- Semifinal round: August 6th (Fri)
- The final round: August 7th (Sat)
- URL: https://mangaoukoku-tosa.jp/manga-koshien30
[ Manga Koshien Gokko ]
An online contest for high school individual students or teams from all over the world who could not participate in the Manga Koshien Finals.
- Work theme: “30” (Free theme as long as “30” is related to the content or visual elements)
- Eligibility for submission: Students whose school level is equivalent to that of high schools in Japan.
- Judging: Submitted works will be displayed on a public website and subject to general voting.
The number of votes cast in the general vote determines the results from 1st to 3rd place.
-
Supplementary prize:
1st place: Wacom Cintiq 16, CLIP STUDIO PAINT EX 2 (Device Plan 2 Year Edition), Sleeping Cat plush toy (big size)
2nd place: CLIP STUDIO PAINT PRO (2 device plan, 2 year subscription), Sleeping Cat plush toy (middle size)
3rd place: CLIP STUDIO TABMATE, Sleeping Cat plush toy (small size)
- Submission period: July 17th (Sat) 0:00 to August 6th (Fri) 16:00 (JST)
- Voting period: July 17th (Sat) 0:00 to August 7th (Sat) 15:00 (JST)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210718005034/en/
Contact information
For Enquiries
Manga Kingdom Tosa Promotion Division, Department of Culture, Community, and Sports, Kochi Prefecture
Email: 141701@ken.pref.kochi.lg.jp
Manga Kingdom Tosa Promotional Committee
Enquiries Regarding this press release
In-Charge: Yasuaki Okamatsu and Maya Nakahira
Manga Kingdom Tosa Promotion Division, Department of Culture, Community, and Sports, Kochi Prefecture
Tel: +81-88-823-9711
Fax: +81-88-823-9296
Email: 141701@ken.pref.kochi.lg.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 16:30:00 EEST | Press release
FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and execution management workflow is becoming increasingly important. FlexTrade's integration with Portx builds on FlexONE's existing real-time front-office risk analytics capabilities, inclu
Xsolla Connect Returns to Brighton13.7.2026 16:22:00 EEST | Press release
Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event will build on that momentum by providing attendees with a dedicated space to connect with peers
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom